PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.78%
Revenue growth above 1.5x AVGO's 6.32%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
11.54%
Gross profit growth above 1.5x AVGO's 4.96%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
30.81%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
30.81%
Operating income growth above 1.5x AVGO's 1.00%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
30.60%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
30.00%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
30.91%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
1.12%
Share count expansion well above AVGO's 0.15%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.92%
Diluted share count expanding well above AVGO's 0.70%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
8.03%
OCF growth at 75-90% of AVGO's 9.32%. Bill Ackman would demand better working capital management or cost discipline.
11.97%
FCF growth 1.25-1.5x AVGO's 9.56%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
633.56%
10Y revenue/share CAGR above 1.5x AVGO's 416.86%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
82.72%
5Y revenue/share CAGR at 50-75% of AVGO's 134.28%. Martin Whitman would worry about a lagging mid-term growth trajectory.
86.88%
3Y revenue/share CAGR 1.25-1.5x AVGO's 62.33%. Bruce Berkowitz might see better product or regional expansions than the competitor.
6238.44%
10Y OCF/share CAGR above 1.5x AVGO's 580.47%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
41278.76%
5Y OCF/share CAGR above 1.5x AVGO's 92.77%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
1144.41%
3Y OCF/share CAGR above 1.5x AVGO's 39.51%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
1477.23%
Net income/share CAGR above 1.5x AVGO's 869.72% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
2644.50%
5Y net income/share CAGR above 1.5x AVGO's 414.43%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
2975.01%
3Y net income/share CAGR above 1.5x AVGO's 16.00%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1576.12%
10Y equity/share CAGR above 1.5x AVGO's 862.23%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
113.56%
5Y equity/share CAGR at 50-75% of AVGO's 165.61%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
88.08%
Below 50% of AVGO's 201.93%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.83%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-16.93%
Inventory is declining while AVGO stands at 8.08%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
8.40%
Asset growth above 1.5x AVGO's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
6.65%
1.25-1.5x AVGO's 5.15%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
-0.23%
Our R&D shrinks while AVGO invests at 13.26%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
0.88%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.